Moderna Inc. said on Tuesday its closely watched flu vaccine did not meet the criteria for early success in a late-stage trial, sending its shares down nearly 5% premarket.
Johnson & Johnson’s second attempt to resolve talc lawsuits in bankruptcy should be dismissed as an unprecedented fraud designed to deny plaintiffs just compensation, lawyers representing cancer victims argued in a Monday court filing.
The U.S. government is spending over $5 billion on an effort to speed up the development of new COVID-19 vaccines and treatments, a Department of Health and Human Services (HHS) spokesperson and a Biden administration official said on Monday.
Biogen is laying off an unspecified number of employees, according to a article published Monday by the Boston Business Journal.
The U.S. Food and Drug Administration (FDA) plans to hold a meeting of its outside experts in June to discuss full approval of the Alzheimer’s drug developed by Eisai Co. Ltd. and Biogen Inc. according to a federal filing on Monday.
Sobi has announced a streamlining and simplification of the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca.
Merck & Co. Inc. and Eisai Co. Ltd. said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.
The Inflation Reduction Act (IRA), signed into law by President Biden on August 2022, also contains provisions regarding drug pricing. Two policies in particular are designed to influence drug prices, and these might in turn affect drug development strategies.
Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.
The combination treatment of AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) met its primary endpoint in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to an interim analysis of the study released Wednesday.